Abstract：
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines. This \'Vaccine Value Profile\' (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.
摘要：
单纯疱疹病毒1型（HSV-1）和2型（HSV-2）是慢性，高度流行的病毒感染在世界各地引起显著的发病率。HSV-2是性传播的，是生殖器溃疡（GUD）的主要原因。它还增加了感染艾滋病毒的风险，助长了艾滋病毒的流行。HSV-1通常在儿童期通过非性接触获得，并有助于口腔和眼部疾病。但它也可以通过性传播导致GUD。HSV-1和HSV-2均可引起新生儿疱疹和神经系统疾病。鉴于HSV-1和HSV-2感染的普遍性以及现有的预防和控制措施有限，疫苗接种将是降低与HSV感染相关的全球发病率负担的最有效策略.疫苗策略包括预防性疫苗接种，这将防止易感人群感染，并可能给予青少年，和治疗性疫苗接种，将给予有症状的生殖器HSV-2感染的人。本文讨论了这两种疫苗的疫苗价值概况。本“HSV疫苗价值概况”(VVP)旨在提供高水平的、全面评估目前可用于潜在公共卫生的信息和数据，管道疫苗和疫苗类产品的经济和社会价值。这个VVP是由学术界的主题专家开发的，非营利组织,政府机构和多边组织。所有贡献者都对HSVVVP的各个要素具有广泛的专业知识，并共同致力于确定当前的研究和知识差距。VVP是仅使用现有的和公开的信息开发的。
